Mr. Michael Moore reports

ONCOLYTICS BIOTECH PROVIDES CORPORATE AND CLINICAL UPDATE

Oncolytics Biotech Inc. will provide a corporate update in a conference call and webcast, covering both business and clinical development activities. Management will host a webcast and conference call on Sept. 20 at 8:30 a.m. EDT to discuss the update in detail with investors and analysts.

Oncolytics continues to pursue its registration pathway in metastatic breast cancer with a goal of an approval for pelareorep. The conference call will outline the status of all supported clinical studies, as well as update on partnering and collaborations.

Webcast and conference call

Oncolytics management will host a conference call for analysts and institutional investors regarding this announcement on Sept. 20, 2018, at 8:30 a.m. ET. The live call may be accessed by dialling 888-231-8191 for callers in North America. Overseas callers should contact investor relations for the toll-free dial information for their country. A replay of this call will be available approximately two hours after the call is ended at 855-859-2056, using the replay code 6090169 and will be available for six months.

A live audio webcast of the call will be accessible on the investor relations page of Oncolytics's website and will be archived for six months.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumour lysis and promotes an inflamed tumour phenotype -- turning cold tumours hot -- through innate and adaptive immune responses to treat a variety of cancers. Oncolytics's clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumour lysis, immunotherapy and immune modulator (IMiD) combinations to produce innate and adaptive immune responses. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.

We seek Safe Harbor.